文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌诊断方式对根治性肾输尿管切除术后膀胱内复发的影响:单中心系列与更新荟萃分析

The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis.
PubMed 文献 · J Urol · 2021-04-28

本研究纳入834例接受根治性肾输尿管切除术(RNU)的上尿路尿路上皮癌(UTUC)患者,按诊断方式分组比较术后膀胱内复发。输尿管镜活检组2年膀胱内复发率为21.9%,多因素分析显示其复发风险显著高于未行输尿管镜或经皮活检组(HR 1.40,p=0.04);经皮活检或未活检的输尿管镜不影响复发。荟萃分析纳入11项其他系列,输尿管镜活检与膀胱内复发相关(HR 1.47,p<0.01)。

要点

  • RNU前输尿管镜活检与膀胱内复发风险增加相关(HR 1.40)。
  • 经皮活检或未活检的输尿管镜未显示与膀胱内复发相关。
  • 输尿管镜活检后膀胱内化疗的临床试验有必要开展。

核心结论

  • RNU前输尿管镜活检,而非经皮活检或未活检的输尿管镜,与膀胱内复发增加相关。

研究设计与样本

  • 单中心回顾性队列纳入1995至2019年接受RNU的834例UTUC患者,按诊断方式分组比较膀胱内复发。
  • 采用Kaplan-Meier分析和Cox比例风险模型,并将第4组与第1组比较结果与文献进行固定效应荟萃分析。

主要发现

  • 834例中,210例(25.2%)未行输尿管镜或经皮活检,57例(6.6%)经皮活检,125例(15.0%)未活检的输尿管镜,442例(53.0%)输尿管镜活检。
  • 四组2年膀胱内复发率分别为15.0%、12.7%、18.4%和21.9%(p=0.09)。
  • 多因素分析显示,输尿管镜活检组(第4组)膀胱内复发风险高于第1组(HR 1.40,p=0.04),经皮活检组(HR 1.07,p=0.87)和未活检输尿管镜组(HR 1.15,p=0.54)无显著差异。
  • 校正RNU后膀胱镜监测频率的亚组分析中,输尿管镜活检仍与膀胱内复发相关。
  • 荟萃分析纳入11项其他系列,输尿管镜活检与膀胱内复发相关(HR 1.47,p<0.01)。

临床怎么用

  • UTUC术前诊断决策时,应权衡输尿管镜活检带来的膀胱内复发风险,尤其对拟行RNU的患者。
  • 输尿管镜活检后应考虑膀胱内化疗以降低膀胱内复发,但需临床试验验证。

局限性

  • 单中心回顾性设计,可能存在选择偏倚和未测量混杂因素。
  • 原文未报告荟萃分析的异质性评估及具体研究间差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Diagnostic ureteroscopic biopsy for upper tract urothelial carcinoma (UTUC) has been hypothesized to increase intravesical recurrence of urothelial carcinoma after radical nephroureterectomy (RNU). Moreover, the impact of ureteroscopy without biopsy or percutaneous biopsy on intravesical recurrence remains unknown. Herein, we compared post-RNU intravesical recurrences across UTUC diagnostic modalities. MATERIALS AND METHODS: Patients undergoing RNU at our institution between 1995 and 2019 were categorized by UTUC diagnostic modality: 1) no ureteroscopy or percutaneous biopsy; 2) percutaneous biopsy; 3) ureteroscopy without biopsy; 4) ureteroscopic biopsy. Intravesical recurrences were compared using Kaplan-Meier analyses and Cox-proportional hazard models. Results of group 4 vs 1 were pooled with the literature using a fixed effects meta-analysis. RESULTS: In a cohort of 834 RNU patients, 210 (25.2%) had undergone no ureteroscopy, 57 (6.6%) percutaneous biopsy, 125 (15.0%) ureteroscopy without biopsy, and 442 (53.0%) ureteroscopic biopsy. Two-year intravesical recurrence rates were 15.0%, 12.7%, 18.4%, and 21.9% for groups 1 through 4, respectively (p=0.09). Multivariable analysis found that group 4 had increased intravesical recurrences (HR 1.40, p=0.04) relative to group 1 while group 2 (HR 1.07, p=0.87) and group 3 (HR 1.15, p=0.54) did not. Group 4 remained associated with intravesical recurrence on subset analyses accounting for post-RNU surveillance cystoscopy frequency. On meta-analysis including 11 other series, ureteroscopic biopsy was associated with intravesical recurrence (HR 1.47, p <0.01). CONCLUSIONS: Ureteroscopic biopsy before RNU, but not percutaneous biopsy or ureteroscopy without biopsy, was associated with increased intravesical recurrence. Clinical trials of intravesical chemotherapy after ureteroscopic biopsy are warranted to reduce intravesical recurrences.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Sharma V, Miest TS, Juvet TS, et al. The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. J Urol. 2021. PMID: 33908802. doi:10.1097/JU.0000000000001834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。